[Screening audiological control in children of different ages after taking ototoxic medications]
M R Bogomilsky1, Yu S Ishanova2, I V Rakhmanova2
1Pirogov Russian National Research Medical University of the Ministry of Health of Russia, Department of Otolaryngology of Pediatric Faculty, Moscow, Russia, 117997.
Insights
Ototoxic drug screening in children revealed middle ear issues in 15.4% and auditory function impairment in 28.2% via distortion product otoacoustic emission (DPOAE). Early signs include reduced amplitude at 4 kHz.
Area of Science:
- Pediatric Audiology
- Ototoxic Drug Monitoring
- Hearing Health
Background:
- Ototoxic therapies pose risks to auditory function in children.
- Early detection of hearing impairment is crucial for developmental outcomes.
Purpose of the Study:
- To compare auditory function during screening of children across different age groups undergoing ototoxic therapy.
- To identify early indicators of ototoxicity in pediatric patients.
Main Methods:
- Auditory function assessment using distortion product otoacoustic emission (DPOAE), short-latency evoked potentials (SLEP), and tympanometry.
- Statistical analysis using Statgraphics Centurion XV.
Main Results:
- Tympanometry identified middle ear pathologies in 15.4% of children with cystic fibrosis on ototoxic treatment.
- Distortion product otoacoustic emission (DPOAE) indicated impaired auditory function in 28.2% of cases.
- Early ototoxicity manifested as decreased amplitude at 4 kHz and DP-gram shifts.
Conclusions:
- Audiological monitoring, including tympanometry and evoked otoacoustic emissions, is recommended for children with a history of ototoxic drug exposure.
- Regular audiological assessments aid in the early detection and management of hearing deficits in pediatric patients.
Aim:
To compare auditory function during screening of children of different age groups who received ototoxic therapy.
Patients And Methods:
Auditory function was studied in various categories of children receiving ototoxic drugs. Hearing was assessed by the registration of distortion product otoacoustic emission (DPOAE), short-latency evoked potentials (SLEP), tympanometry. Statistical processing was performed using the C program Statgraphics Centurion XV.
Results:
In this study, screening of auditory function in children suffering from cystic fibrosis and receiving ototoxic treatment revealed pathologic conditions of the middle ear according to tympanometry in 15.4% of cases, impaired auditory function in 28.2% of cases according to DPOAE. Early ototoxicosis presented as a decrease in the amplitude of the response at a frequency of 4 kHz, and a change in the structure of the DP-gram in the form of a shift to the low-frequency area. Examination of the auditory function of premature infants receiving potentially ototoxic drugs in the early neonatal period demonstrated that the administration of ototoxic drugs does not affect the maturation of outer hair cells.
Conclusion:
Audiological control, such as tympanometry and registration of evoked otoacoustic remission should be included in the outpatient observation of children with a history of ototoxic drugs.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion